Last reviewed · How we verify

JNJ-54861911 - Supratherapeutic Dose

Janssen Research & Development, LLC · Phase 1 active Small molecule

JNJ-54861911 - Supratherapeutic Dose is a Small molecule drug developed by Janssen Research & Development, LLC. It is currently in Phase 1 development. Also known as: RSC-385896, MTS-0385896A.

At a glance

Generic nameJNJ-54861911 - Supratherapeutic Dose
Also known asRSC-385896, MTS-0385896A
SponsorJanssen Research & Development, LLC
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about JNJ-54861911 - Supratherapeutic Dose

What is JNJ-54861911 - Supratherapeutic Dose?

JNJ-54861911 - Supratherapeutic Dose is a Small molecule drug developed by Janssen Research & Development, LLC.

Who makes JNJ-54861911 - Supratherapeutic Dose?

JNJ-54861911 - Supratherapeutic Dose is developed by Janssen Research & Development, LLC (see full Janssen Research & Development, LLC pipeline at /company/johnson-johnson).

Is JNJ-54861911 - Supratherapeutic Dose also known as anything else?

JNJ-54861911 - Supratherapeutic Dose is also known as RSC-385896, MTS-0385896A.

What development phase is JNJ-54861911 - Supratherapeutic Dose in?

JNJ-54861911 - Supratherapeutic Dose is in Phase 1.

Related